[1] Moosavy SH,Davoodian P,Nazarnezhad MA,et al. Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. Electron Physician, 2017, 9: 5646-5656.
[2] Song AT,Avelino-Silva VI,Pecora RA,et al. Liver transplantation: fifty years of experience. World J Gastroenterol, 2014, 20: 5363-5374.
[3] Moyer VA. Screening for hepatitis C virus infection in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med, 2013, 159: 349-357.
[4] Halota W,Flisiak R,Juszczyk J,et al. Recommendations for the treatment of hepatitis C in 2017. Clin Exp Hepatol, 2017, 3: 47-55.
[5] Jakobsen JC,Nielsen EE,Feinberg J,et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev, 2017, 9: CD012143.
[6] 中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2015更新版). 肝脏, 2015, 20: 933-949,1006.
[7] Wray CM,Davis AM. Screening for hepatitis C. JAMA, 2015, 313: 1855-1856.
[8] Liver EAftSot. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol, 2018.
[9] Ferrarese A,Zanetto A,Gambato M,et al. Liver transplantation for viral hepatitis in 2015. World J Gastroenterol, 2016, 22: 1570-1581.
[10] Forman LM,Lewis JD,Berlin JA,et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology, 2002, 122: 889-896.
[11] Huesing-Kabar A,Dohna CZ,Heinzow H,et al. Risk factors for allograft failure in liver transplant recipients. Z Gastroenterol, 2018.
[12] Te HS. Recurrent hepatitis C: the bane of transplant hepatology. Hepatology, 2014, 59: 21-23.
[13] Petrara MR,Giunco S,Serraino D,et al. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment. Cancer Lett, 2015, 369: 37-44.
[14] Wong RJ,Saab S,Ahmed A. Extrahepatic manifestations of hepatitis C virus after liver transplantation. Clin Liver Dis, 2017, 21: 595-606.
[15] Kogiso T,Hashimoto E,Ikarashi Y,et al. Spontaneous clearance of HCV accompanying hepatitis after liver transplantation. Clin J Gastroenterol, 2015, 8: 323-329.
[16] Elsiesy H,Abaalkhail F,Al Sebayel M,et al. Spontaneous clearance of hepatitis C genotype 4 after liver retransplantation. Transplant Proc, 2015, 47: 1234-1237.
[17] European Association for the Study of the Liver. EAftSot. EASL recommendations on treatment of hepatitis C 2018. J Hepatol, 2018, 69: 461-511.
[18] Everson GT,Terrault NA,Lok AS,et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology, 2013, 57: 1752-1762.
[19] Hezode C,Fontaine H,Dorival C,et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol, 2013, 59: 434-441.
[20] Terrault NA,McCaughan GW,Curry MP,et al. International liver transplantation society consensus statement on hepatitis C management in liver transplant candidates. Transplantation, 2017, 101: 945-955.
[21] Charlton M,Everson GT,Flamm SL,et al. Ledipasvir and Sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology, 2015, 149: 649-659.
[22] Manns M,Samuel D,Gane EJ,et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis, 2016, 16: 685-697.
[23] Lionetti R,Calvaruso V,Piccolo P,et al. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. Clin Transplant, 2018, 32.
[24] Degasperi E,Aghemo A,Paolucci S,et al. 12 weeks ombitasvir/paritaprevir-ritonavir+ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis. Dig Liver Dis, 2018.
[25] Houssel-Debry P,Coilly A,Fougerou-Leurent C,et al. 12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation. Hepatology, 2018.
[26] Salcedo M,Prieto M,Castells L,et al. Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study. Transpl Int, 2017, 30: 1041-1050.
[27] Reau N,Kwo PY,Rhee S,et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. Hepatology, 2018.
[28] Beinhardt S,Al-Zoairy R,Kozbial K,et al. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation. Liver Int, 2017.
[29] Antonini TM,Coilly A,Rossignol E,et al. Sofosbuvir-based regimens in HIV/HCV coinfected patients after liver transplantation: results from the ANRS CO23 CUPILT study. Transplantation, 2018, 102: 119-126.
[30] Martini S,Sacco M,Strona S,et al. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis. Liver Int, 2017, 37: 62-70. |
